The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease-Reference-Cited by-同舟云学术

The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease

Published:2022-12-06 Issue:3 Volume:384 Page:382-392
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Reinhart Glenn A.,Harrison Paul C.,Lincoln Kathleen,Chen Hongxing,Sun Peng,Hill Jon,Qian Hu Sheng,McHugh Mark C.,Clifford Holly,Ng Khing Jow,Wang Hong,Fowler Danielle,Gueneva-Boucheva Kristina,Brenneman Jehrod B.,Bosanac Todd,Wong Diane,Fryer Ryan M.,Sarko Chris,Boustany-Kari Carine M.,Pullen Steven S.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference26 articles.

1. Renal histologic changes and the outcome in patients with diabetic nephropathy

2. A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat

3. Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease;Bénardeau;Naunyn Schmiedebergs Arch Pharmacol,2021

4. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

5. Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysis;Dellamea;BMC Med Genet,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic improvement within 27 days of avenciguat treatment in Child-Pugh A cirrhosis detected by an oral cholate challenge test;Liver Transplantation;2024-06-12

2. Effect of Avenciguat on Albuminuria in Patients with CKD;Journal of the American Society of Nephrology;2024-05-25

3. Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509, a soluble guanylyl cyclase activator, in healthy volunteers: Results from two randomized controlled trials;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-05-24

4. Oxidative Stress: A Culprit in the Progression of Diabetic Kidney Disease;Antioxidants;2024-04-12

5. Lessons learned from early-stage clinical trials for diabetic nephropathy;Expert Opinion on Investigational Drugs;2024-03-15